DBV Technologies reported $103.21M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amarin USD 119.52M 1.51M Mar/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
DBV Technologies USD 103.21M 103.21M Jun/2025
Halozyme Therapeutics USD 61.86M 114.47M Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Insmed USD 1.28B 881.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
United Therapeutics USD 1.59B 306.8M Jun/2025